NET CONNECT Scientific Projects presented at ENETS 2021
NET CONNECT Scientific Projects presented at ENETS 2021
Dr. Jorge Hernando, Dr. Aman Chauhan, Dr. Jaume Capdevila, Dr. Panpan Zhang, Dr. Angela Lamarca, Asst. Prof. Louis de Mestier, Dr. Joakim Crona, Dr. Teresa Alonso Gordoa, Dr. Rachel van Leeuwaarde, Asst. Prof. Mauro Cives, Prof. Kjell Öberg, Prof. Marianne Pavel, Dr. Emily Bergsland, Dr. Alia Munir, Dr. Francesca Spada
Results from two NET CONNECT studies were presented as posters at the ENETS 2021 virtual conference.Dr. Jorge Hernando
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...
Spain
Dr. Aman Chauhan
Medical Oncologist
University of Kentucky's Markey Cancer Centre
United States (US)
Dr. Jaume Capdevila
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...
Spain
Dr. Panpan Zhang
Medical Oncologist
Peking University Cancer Hospital & Institute
China
Dr. Angela Lamarca
Medical Oncologist
The Christie NHS Foundation Trust
United Kingdom (UK)
Asst. Prof. Louis de Mestier
Gastroenterologist
Beaujon University Hosptial
France
Dr. Joakim Crona
Clinical Oncology & Molecular Oncology
Uppsala Academic Hospital
Sweden
Dr. Teresa Alonso Gordoa
Medical Oncologist
Hospital Universitario Ramón y Cajal
Spain
Dr. Rachel van Leeuwaarde
Endocrinologist
University Medical Centre Utrecht
Netherlands
Asst. Prof. Mauro Cives
Medical Oncologist
University of Bari
Italy
Prof. Kjell Öberg
Endocrinologist
Uppsala University Hospital
Sweden
Prof. Marianne Pavel
Endocrinologist
University of Erlangen
Germany
Dr. Emily Bergsland
Gastroenterologist
University of California-San Francisco (UCSF)
United States (US)
Dr. Alia Munir
Endocrinologist
Sheffield Teaching Hospital NHS Foundation Trust
United Kingdom (UK)
Dr. Francesca Spada
Medical Oncologist
European Insititute of Oncology
Italy
Dr. Jorge Hernando
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)
Spain
Dr. Jorge Hernando has no relevant financial relationships to disclose.
Dr. Aman Chauhan
Medical Oncologist
University of Kentucky's Markey Cancer Centre
United States (US)
Dr. Aman Chauhan has no relevant financial relationships to disclose.
Dr. Jaume Capdevila
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)
Spain
Dr. Jaume Capdevila obtained his medical degree from the University of Lleida, in Catalonia, Spain. In 2000-2001 he held a fellowship in the department of biochemistry and molecular biology at the University of Lleida. From 2002 to 2006 he attended a specialization in medical oncology at the Santa Creu i Sant Pau University Hospital, Barcelona and since 2006 served as medical oncologist at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Since early 2013 he is also leading the gastrointestinal and endocrine tumor unit at Teknon Cancer Institute. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 82 articles in peer-reviewed journals and several book chapters. He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE, and GETHI) and actively participates in national and international trials. He is member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), Secretary and Treasurer of the Spanish Task Force for neuroendocrine tumors (Grupo Español de Tumores Neuroendocrinos, GETNE) and funding member and Treasurer of the Spanish Task Force Group for Research in Orphan and Rare Tumors (Grupo Español de Tumores Huérfanos e Infrecuentes, GETHI). He is also a medical oncologist member of the Thyroid Cancer Working Group within the Spanish Society of Endocrinology and Nutrition (SEEN).
Dr. Jaume Capdevila has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AAA, Bayer, Eisai, Merck, Novartis, Ipsen, Pfizer and Sanofi.
Dr. Panpan Zhang
Medical Oncologist
Peking University Cancer Hospital & Institute
China
Dr. Panpan Zhang has no relevant financial relationships to disclose.
Dr. Angela Lamarca
Medical Oncologist
The Christie NHS Foundation Trust
United Kingdom (UK)
Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.
Dr. Angela Lamarca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AAA, Bayer, EISAI, Merck, Mylan and Delcath, Novartis, Nutricia, Roche, SrtEx and QED.
Asst. Prof. Louis de Mestier
Gastroenterologist
Beaujon University Hosptial
France
Dr Louis de Mestier serves as Assistant Professor in the Department of Pancreatology - Digestive Oncology at the ENETS Centre of Excellence of Beaujon University Hospital in Clichy (Université Paris-Cité), France. He obtained his specialist diplomas in Hepato-Gastroenterology and Digestive Oncology at the University of Reims, France. He has completed a PhD in Cancer Biology at the University of Paris-Cité in 2021. His clinical interests are on neuroendocrine tumors and pancreatic diseases. His main areas of clinical and translational research include tumor heterogeneity, molecular biomarkers and personalized treatment in NETs. He has been member of the Advisory Board of the French Neuroendocrine Tumor Networks (GTE, RENATEN) since 2020, and joined the Advisory Board of the European Neuroendocrine Tumor Society (ENETS) in 2022. He has participated in more than 100 medical publications, including more than 50 indexed papers in the field of NETs.
Asst. Prof. Louis de Mestier has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Novartis, Pfizer, Ipsen.
Dr. Joakim Crona
Clinical Oncology & Molecular Oncology
Uppsala Academic Hospital
Sweden
Joakim Crona is a resident in clinical oncology and associate professor in molecular oncology at Uppsala Academic Hospital, Sweden. He’s had a particular interest for neuroendocrine tumors since more than eight years. This included successfully defending his thesis covering genetics of neuroendocrine tumors, as well as working as a physician at the clinic of endocrine oncology. Joakim has just returned from a short term fellowship at the Pheochromocytoma/Paraganglioma Program, US National Institutes of Health. He plans a future career in the field of endocrine oncology that will unite clinical science with molecular biology, aiming at improving treatment of patients with these rare diseases.
Dr. Joakim Crona has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Novartis.
Dr. Teresa Alonso Gordoa
Medical Oncologist
Hospital Universitario Ramón y Cajal
Spain
Dr. Teresa Alonso Gordoa is a Medical Oncologist at the Medical Oncology Department of the Hospital Universitario Ramón y Cajal in Madrid. She finalized the degree of medicine by the University of Navarre in 2008 and the medical oncology specialization by the Hospital Universitario Clínico San Carlos in 2013. She is specialized in the care of patients with genitourinary, germ cell and endocrine tumors and in the early drug development unit. In addition, she is a member of the Spanish Society of Medical Oncology (SEOM), the European Society for Medical Oncology (ESMO), the Spanish Society of Genitourinary Oncology (SOGUG), the Germ Cell Group (GG) and the Spanish Group of Neuroendocrine Tumors (GETNE). She participates actively in research projects and clinical trials with international impact. She is a member of the honorary faculty of the University of Alcalá and a reviewer of indexed international journals. She has presented communications in national and international congresses and has participated in the publication of scientific articles in national and international journals.
Dr. Teresa Alonso Gordoa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Astellas, Bayer, BMS, Eusa Pharma, Novartis, Roche, Sanofi Genzyme, Ipsen and Pfizer.
Dr. Rachel van Leeuwaarde
Endocrinologist
University Medical Centre Utrecht
Netherlands
Dr. Rachel van Leeuwaarde has no relevant financial relationships to disclose.
Asst. Prof. Mauro Cives
Medical Oncologist
University of Bari
Italy
Dr. Mauro Cives works as Assistant Professor of Medical Oncology in the Department of Biomedical Sciences and Human Oncology, University of Bari, Italy. He gained his MD degree and specialization degree in Medical Oncology at the University of Bari. From 2013 to 2016 Dr. Cives worked as Research Associate within the Neuroendocrine Program of the Moffitt Cancer Center & Research Institute, Tampa (FL, USA). Dr. Cives’ work focuses on the preclinical and clinical evaluation of innovative treatments for neuroendocrine tumors (NETs). In 2017, Dr. Cives was awarded by the European Neuroendocrine Tumor Society (ENETS) for the project “CAR-T cells for GEP-NETs”. Dr. Cives is co-author of over 30 peer-reviewed papers.
Asst. Prof. Mauro Cives has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AAA and Ipsen.
Prof. Kjell Öberg
Endocrinologist
Uppsala University Hospital
Sweden
Dr. Kjell Öberg is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University. He was the former head of the Department of Endocrine Oncology, University Hospital, and he is a specialist in endocrinology and internal medicine. He founded the Department of Endocrine Oncology at Uppsala University Hospital and has 40 years’ experience in the field of neuroendocrine tumors. Between 1986 and 1992 he was clinical associate director of the Ludwig Institute for Cancer Research. From 1998 to 2002 he was chairman of the Department of Medical Sciences at the Medical Faculty of Uppsala University. July 2002 until June 2008 he was the Dean of the Medical Faculty. He was the chairman of the Centre of Excellence of Endocrine Tumors and Vice chairman of the Department of Endocrine Oncology, University Hospital, Uppsala until May 2013, at present time he is senior advisor at the same department. Currently, Adjunct Professor of Surgery at Vanderbilt University, Nashville, USA. Dr. Öberg was one of the founders and coordinator of the European Neuroendocrine Tumor Network (ENET) 1995-2000 and was past chairman of the Nordic Neuroendocrine Tumor Group. He has pioneered the treatment of carcinoid tumor patients with interferon and somatostatin analogues and developed assays for tumor markers such as Chromogranin A and radiological procedures, including specialized PET scans. In 1988 he was the first to describe a genetic deletion in multiple endocrine neoplasia Type 1 (MEN1). Dr. Öberg has given many hundreds of presentations at international meetings and published more than 500 papers within his research field, H-factor 67 and 14,850 citations. In addition he is the author of numerous chapters on Carcinoid tumors in several international textbooks including William’s Textbook of Endocrinology, Leslie de Groot’s Textbook of Endocrinology, Clinical Endocrinology and Fordtran’s Textbook of Gastroenterology. Dr. Öberg is Editor-in Chief of World Journal of Gastroenterolgy (WJG). In 1991 Dr. Öberg received the European Interferon Research reward. In 2003 he received the award “Eminent Scientist Year 2003” by the International Research Promotion Council (IRPC) and World Scientist Forum and in 2004 he was awarded the European Gold Medal in Endocrinology from the English Endocrine Society. In November 2006 he received the Harry Boström Award Lecture at Swedish Medical Society, and in 2011 the University Hospital Clinical Research Award. In 2014 he received the Rudbeck Medallion for excellence in research and the Life Time Achievement Award from North American Neuroendocrine Society. January 2017 Dr. Öberg was awarded with The Swedish Endocrine Society Gold Medal for prominent research and clinical activities and in March 2017 he received Lifetime Achievement Award by European Neuroendocrine Tumor Society (ENETS). In October of 2017, Lifetime Achievement from Asian Pacific Neuroendocrine Tumor Society (AP-NETS). Dr. Öberg is a member of the Royal Society of Sciences, member of Swedish Society of Medical Research, Honorary member of Finnish Oncology Society, Finnish Endocrine Society and Honorary member of Spanish Neuroendocrine NET-work. Dr. Öberg is Vice President of ENETS since March 2012 and also a member of NANETS Advisory Board as well as several other national and international research and scientific boards and many scientific journal review boards.
Prof. Kjell Öberg has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Novartis, Ipsen and Wren Labatories.
Prof. Marianne Pavel
Endocrinologist
University of Erlangen
Germany
Dr. Emily Bergsland
Gastroenterologist
University of California-San Francisco (UCSF)
United States (US)
Dr. Alia Munir
Endocrinologist
Sheffield Teaching Hospital NHS Foundation Trust
United Kingdom (UK)
Alia Munir trained in Medicine at the University of Wales College of Medicine and began her basic clinical training in Cardiff and South Wales. She then began her specialist training in Guy’s and St Thomas’ London and later completed her higher medical training in Diabetes, Endocrinology and General Internal Medicine at Sheffield Teaching Hospitals (STH). She was awarded The Society for Endocrinology Clinical Trust Research Fellowship and obtained a PhD in Professor Newell-Prices’ laboratory, focussing on RNA interference as a Therapy for Cushing’s Disease, leading to a patent and orphan drug designation. She was also awarded the Yorkshire Enterprise Fellowship. She was chair of the Young Endocrinologists Scientific Steering Committee for the Society for Endocrinology during this time. She was appointed Consultant in Diabetes and Endocrinology in Pinderfields Hospital, Mid Yorkshire 2011-2015. She was also appointed Consultant Endocrinologist in STH and coordinated Sheffield’s successful European Neuroendocrine Tumour Society Centre of Excellence award in 2016. She has lead in a joint working partnership with Novartis and been part of the 4th Wave Education programme with Ipsen. Dr Munir’s main clinical interests are in neuroendocrinology and high risk diabetic pregnancy, and is responsible for general medical inpatients and participates in the medical take.
Dr. Alia Munir has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Novartis and Ipsen.
Dr. Francesca Spada
Medical Oncologist
European Insititute of Oncology
Italy
|
5 min
|
Mar 2021
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
NET CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen and from Eisai Europe Limited.
Other programmes of interest
Other programmes developed by Dr. Jorge Hernando
Dr. Jorge Hernando
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...
Spain
Other programmes developed by Dr. Aman Chauhan
Dr. Aman Chauhan
Medical Oncologist
University of Kentucky's Markey Cancer Centre
United States (US)
Other programmes developed by Dr. Jaume Capdevila
Dr. Jaume Capdevila
Medical Oncologist
Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...
Spain
Other programmes developed by Dr. Angela Lamarca
Other programmes developed by Asst. Prof. Louis de Mestier
Other programmes developed by Dr. Joakim Crona
Dr. Joakim Crona
Clinical Oncology & Molecular Oncology
Uppsala Academic Hospital
Sweden
Other programmes developed by Dr. Teresa Alonso Gordoa
Other programmes developed by Dr. Rachel van Leeuwaarde
Other programmes developed by Asst. Prof. Mauro Cives
Other programmes developed by Prof. Marianne Pavel
Other programmes developed by Dr. Alia Munir
Dr. Alia Munir
Endocrinologist
Sheffield Teaching Hospital NHS Foundation Trust
United Kingdom (UK)